Last reviewed · How we verify
IBI-323 combined with bevacizumab plus Platinum
IBI-323 combined with bevacizumab plus Platinum is a Small molecule drug developed by Hunan Province Tumor Hospital. It is currently in Phase 2 development.
At a glance
| Generic name | IBI-323 combined with bevacizumab plus Platinum |
|---|---|
| Sponsor | Hunan Province Tumor Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI-323 combined with bevacizumab plus Platinum CI brief — competitive landscape report
- IBI-323 combined with bevacizumab plus Platinum updates RSS · CI watch RSS
- Hunan Province Tumor Hospital portfolio CI
Frequently asked questions about IBI-323 combined with bevacizumab plus Platinum
What is IBI-323 combined with bevacizumab plus Platinum?
IBI-323 combined with bevacizumab plus Platinum is a Small molecule drug developed by Hunan Province Tumor Hospital.
Who makes IBI-323 combined with bevacizumab plus Platinum?
IBI-323 combined with bevacizumab plus Platinum is developed by Hunan Province Tumor Hospital (see full Hunan Province Tumor Hospital pipeline at /company/hunan-province-tumor-hospital).
What development phase is IBI-323 combined with bevacizumab plus Platinum in?
IBI-323 combined with bevacizumab plus Platinum is in Phase 2.